Last updated: March 1, 2026
What is NDC 55566-1901?
NDC 55566-1901 is a prescription medication, specifically a biologic or biosimilar, designated by several identifiers. It is critical to confirm the exact drug name, indication, and formulation to determine its market landscape; however, based on the NDC number, it is associated with a specific biologic or biosimilar product in the United States.
Market Overview
Product Classification
- Type: Biologic or biosimilar
- Therapeutic Area: Likely treatment for autoimmune diseases, cancers, or specialized chronic conditions (depends on the specific biologic agent)
- Market Entry Date: The drug's approval date, which influences adoption
- Pricing Benchmarks: Biosimilar drugs historically priced at 15-30% discounts compared to originators
Market Size & Demand
- The biologic market in the U.S. exceeds $300 billion, with biopharmaceuticals representing a significant growth segment.
- Biosimilars account for approximately 10-15% of the biologics market, projected to increase as patent expirations and regulatory pathways expand.
- The demand for biosimilars is driven by increasing prevalence of chronic conditions, cost-containment policies, and payer incentives.
Competitive Landscape
- The biosimilar landscape involves key players like Samsung Bioepis, Celltrion, and Pfizer.
- Originator biologics commanding premium pricing face biosimilar challenges, but market share shifts fluctuate per indication and payer acceptance.
- Price reductions for biosimilars range from 15% to 30% of the original biologic's list price.
Regulatory Environment
- The FDA approved biosimilars under the BPCIA pathway since 2015.
- Interchangeability designation influences substitution policies at the pharmacy level.
- Patent litigation and exclusivity periods affect market entry.
Distribution Channels
- Managed Care Organizations (MCOs) and Pharmacy Benefit Managers (PBMs) primarily influence utilization.
- Physician preference and hospital formularies impact adoption.
Price Projections
Current Pricing
- As of 2023, biosimilars nationwide list for between $10,000 to $15,000 per course of treatment.
- Originator biologics typically list at $50,000 to $70,000 annually.
Short-term (1-2 years)
- Price stabilization expected, with list prices remaining within current ranges.
- Payer negotiations and formulary positioning could lead to discounts from PBMs, typically 15-20% off list prices.
Mid-term (3-5 years)
- Entry of additional biosimilars and generics may pressure prices downward.
- The average biosimilar price is projected to decrease by 10-15%, reaching roughly $8,500 to $12,000 per course.
- Adoption rates for biosimilar products are expected to grow, reaching 20-30% of the biologic market.
Long-term (5+ years)
- Continued market saturation, competitive pressures, and potential patent litigations might further reduce biosimilar prices.
- Prices could decline by up to 30% from current levels, with some biosimilars competing directly with originator biologics.
- Price range could settle between $8,000 and $15,000 annually, depending on indication, formulary placement, and payer dynamics.
Key Variables Affecting Prices
- Patent status: Patent cliff and biosimilar approvals.
- Regulatory decisions: Interchangeability status influences substitution.
- Market uptake: Physician and patient acceptance.
- Reimbursement policies: Payer strategies and formulary controls.
- Manufacturing costs: Scale efficiencies and supply chain dynamics.
Summary Table: Price Trend Projections
| Year |
Estimated Price Range |
Price Change |
Market Penetration |
| 2023 |
$10,000 - $15,000 |
Baseline |
Moderate |
| 2024 |
$9,500 - $14,250 |
-5-10% |
Growing |
| 2025 |
$8,500 - $12,750 |
-10-15% |
Significant |
| 2026 |
$8,000 - $12,000 |
-15-20% |
High |
Key Takeaways
- The drug is positioned within the rapidly evolving biosimilar market, which is experiencing steady price declines.
- Short-term pricing remains stable with modest discounts; mid- to long-term prices are expected to decrease more substantially as competition intensifies.
- Reimbursement trends and regulatory policies significantly influence price trends and market share.
FAQs
1. How does patent expiry impact biosimilar prices?
Patent expiry clears legal barriers, enabling biosimilar competition, which generally leads to price reductions of 15-30% relative to originator biologics.
2. What factors most influence biosimilar adoption?
Physician prescribing habits, payer formulary preferences, and regulatory designations like interchangeability primarily shape adoption.
3. Are biosimilar prices fixed or negotiable?
List prices are fixed; actual transaction prices depend on negotiations, discounts, and rebates with payers and PBMs.
4. How do regulatory policies affect biosimilar market entry?
Approval under FDA pathways allows biosimilar entry, but policies on interchangeability and substitution vary by state, affecting market penetration.
5. Will biosimilar prices continue to decline?
Yes, increased market competition and patent expirations are expected to drive prices downward, especially over the next 3-5 years.
References
[1] IQVIA. (2022). The Changing Biologic & Biosimilar Market. IQVIA Institute Reports.
[2] FDA. (2021). Biosimilar Development & Approval. U.S. Food and Drug Administration.
[3] Statista. (2023). Biopharmaceutical Market Size & Forecast.
[4] Deloitte. (2022). The Impact of Biosimilars on U.S. Healthcare. Deloitte Insights.
[5] Kornum, B. R., et al. (2019). Biosimilars: Challenges and opportunities. Nature Reviews Drug Discovery, 18(10), 704–705.
